Aarons Sallyanne, Peisah Carmelle, Wijeratne Chanaka
School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia.
Australas J Ageing. 2012 Sep;31(3):198-202. doi: 10.1111/j.1741-6612.2012.00632.x.
Advances in the treatment of Parkinson's disease have led to significant improvement in many of the disabling motor symptoms of the disease, but often at the cost of neuropsychiatric side-effects. These include psychosis, dopamine dysregulation syndrome, impulse control disorders, mood disorders and Parkinson's disease drug withdrawal syndromes. Such side-effects can be as disabling and have as much impact on activities of daily living, quality of life, relationships and caregiver burden as motor symptoms. Awareness of these potential side-effects is important both in terms of obtaining informed consent, and to aid early identification and intervention, as patients may not spontaneously report side-effects because of lack of insight, or deny them out of shame or embarrassment. The challenge of treatment can be a trade off between the emergence of such side-effects and the amelioration of parkinsonism, best mastered with an informed dialogue between clinician and patient.
帕金森病治疗方面的进展已使该疾病许多致残性运动症状得到显著改善,但往往是以出现神经精神副作用为代价。这些副作用包括精神病、多巴胺调节障碍综合征、冲动控制障碍、情绪障碍以及帕金森病药物戒断综合征。此类副作用可能同样具有致残性,并且对日常生活活动、生活质量、人际关系及照料者负担的影响与运动症状一样大。认识到这些潜在副作用,对于获得知情同意以及帮助早期识别和干预都很重要,因为患者可能由于缺乏洞察力而不会主动报告副作用,或者出于羞耻或尴尬而否认它们。治疗面临的挑战在于如何在出现此类副作用与改善帕金森症状之间进行权衡,这最好通过临床医生与患者之间的充分沟通来把握。